NCT01180348View on ClinicalTrials.gov

Efficacy and Safety of a New Botulinum Toxin Type A for Treatment of Facial Expression Lines

PHASE3CompletedINTERVENTIONAL

Enrollment

192

Participants

Timeline

Start Date

August 31, 2011

Primary Completion Date

October 31, 2011

Study Completion Date

September 30, 2012

Conditions

Wrinkles

Interventions

DRUG

Botulift

Application of 90 U of Botulift divided in 3 applications on each side of the face in fifteen predetermined sites in three regions of the face (front, glabellar, periocular).

DRUG

Botox

Application of 90 U of Botox divided in 3 applications on each side of the face in fifteen predetermined sites in three regions of the face (front, glabellar, periocular).

Trial Locations (1)

13276254

LAL Clinica Pesquisa e Desenvolvimento Ltda, Valinhos

All Listed Sponsors

collaborator

Laboratório Químico Farmacêutico Bergamo Ltda.

INDUSTRY

lead

Azidus Brasil

INDUSTRY

NCT01180348 - Efficacy and Safety of a New Botulinum Toxin Type A for Treatment of Facial Expression Lines | Biotech Hunter | Biotech Hunter